Bispecific antibodies Loading... : Investor Sentiment and Bull/Bear Views
Loading chart...
Top Calls
No data yet
Price change since each call, adjusted for long/short direction. Results calculated:
Feed
03:46
Jan 15
Jan 15
Bispecific antibodies lead oncology deal-making.
Bispecific antibodies are the current core of large oncology deal-making. Among oncology deals above $100 million, bispecifics account for about 60%, and upfront payments have risen sharply, showing big pharma is pricing the technology as a present rather than future theme.
HIGH
11:01
Jan 02
Jan 02
Bio subthemes rotate within Korean market.
Within Korean biotech, Kim expects several themes to rotate: ADC, bispecific antibodies, obesity, MASH, dementia, and hair loss where policy issues have emerged. He views these as smaller thematic trades rather than one single sector call.
MED
About Bispecific antibodies Investor Commentary
Across the available history and selected sources, Buzzberg tracks Bispecific antibodies across 2 sources: 1 bullish vs 0 bearish calls from 2 authors. Historical directional balance: 50% = 100 × (bullish − bearish) / all deduplicated idea records, including other directions. This is neither a probability of a price rise nor the share of bullish authors. 2 total trade ideas tracked. Latest voices: Lee Kyung-ho, Kim Dong-yeop.